New drug tested for Tough-to-Treat blood cancer
NCT ID NCT01198067
Summary
This early-phase study aimed to find the safest and most effective dose of the drug pomalidomide for patients with Waldenstrom macroglobulinemia, a rare blood cancer that had returned or stopped responding to prior treatments. The trial enrolled 15 patients to carefully monitor side effects and see if the drug could help control the cancer. The main goal was to understand how much of the drug patients could tolerate, not to prove it was a cure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT WALDENSTROM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.